Become a MemberHomeJoin Mailing ListContact Us

Call for Papers



Abstract Notifications sent to PRESENTING authors on July 30, 2013.


If you are the presenting author of an abstract and did not receive a notification email,

please contact us at


We would like to thank everyone who submitted an abstract.

We are pleased to announce that we have received a record number of more than 2,300 abstracts.




Abstracts are now available



Submission Guidelines

Submission Categories

Clinical Trials in Progress

Submission/Abstract Deadlines

Late Breaking Abstract Submission

ACCME Information

Media and Embargo Policy




Submission Guidelines


  • Research work should be original and innovative. Work can be presented prior to the 15th WCLC, but MUST include new information
  • Abstracts must be submitted electronically through the Conference website, click here to submit your abstract >>
  • Abstracts will be accepted in English only
  • Abstracts should not exceed 500 words in length (authors and abstract title do not count towards word limit, the word limit applies to the abstract body only)
  • Tables may be included and each will count as 100 words
  • A maximum of 2 images may be included, each will count as 100 words
  • The abstract must be structured as follows. Each section must be completed. If one section is not applicable, please put 'not applicable' in the text box
    • Background
    • Methods
    • Results
    • Conclusion
  • The following information is mandatory for each co-author. Information highlighted in bold is only mandatory for presenting and submitting authors.
    • First Name
    • Family Name
    • Institution
    • City
    • Country
    • Email Address
    • Phone
  • The author indicated as the presenting author must be registered for the meeting. The presenting author is also the main contact person and will receive all correspondence such as notification of acceptance, presentation details and guidelines, etc. It is the presenting author's responsibility to provide this information to his co-authors.
  • There is no limit to the number of co-authors per abstract
  • There is no fee for submitting an abstract
  • There is no limit to the number of abstracts you may submit (however, an individual may not be offered more than 2 oral presentations)
  • An international panel of reviewers will review all abstracts anonymously
  • All abstracts accepted by the Scientific Committee will be published in the Journal of Thoracic Oncology and on the Conference website prior to the meeting. It is mandatory to agree to this at the time of submission
  • CME disclosure information needs to be completed for EACH co-author at the time of submission through the online abstract submission form; however, information can be provided by the submitting author


Submission Categories


    a. Cancer Biology
    b. Novel Cancer Genes and Pathways
    c. Technology and Model Development
    d. Tumor Immunology
    a. Preclinical Models of Therapeutics/Imaging
    b. Prognostic and Predictive Biomarkers
    a. Surgery
    b. Radiotherapy
    c. Chemotherapy
    d. Combined Modality
    e. Non-Small Cell Lung Cancer

i. Advanced Stage

1. Chemotherapy

2. Novel Therapies

ii. Early Stage

    f. Small-Cell Lung Cancer
    g. Mesothelioma
    h. Thymoma
    i. Esophagus
    j. Other Thoracic Malignancies
    k. Bronchoscopy, Endoscopy
    l. Imaging
    m. Pathology
    a. Early Detection and Screening
    b. Diagnosis and Staging
    c. Epidemiology, Etiology
    d. Tobacco Control, Prevention, and Chemoprevention
    a. Presentation
    b. Clinical Cases
    c. Paraneoplastic Syndromes
    d. Nursing
    e. Palliative Care
    f. Supportive Care
    g. Advocacy



Clinical Trials in Progress


The Conference will accept abstracts on Clinical Trials in Progress. Please submit your abstract under the most appropriate category. If you are not able to complete each section (Background, Methods, Results, Conclusion), please enter 'not applicable' in this section.



Abstract Deadlines


  Abstract Submission CLOSED
  Abstract Submission Deadline June 21, 2013 (23:59 PST) - Extended: June 24, 2013 (17:00 PST)
  Scholarship Application Deadline June 21, 2013 (23:59 PST) - Extended: June 24, 2013 (17:00 PST)
  Author Notification June 26, 2013 - Sent: July 30, 2013
  Early Registration Deadline August 2, 2013 (23:59 PST) - Extended: August 9, 2013 (23:59 PST)
  Abstract Presentation Confirmation Deadline August 16, 2013 (23:59 PST)
  Late Breaking Abstract Submission Deadline August 30, 2013 (23:59 PST)
  Presenting Author and Abstract Title Changes Deadline September 6, 2013 (23:59 PST)
  Presenting Author Registration Deadline September 6, 2013 (23:59 PST)



Late Breaking Abstract Submission


The Conference will allow late breaking submission privileges for


  • Randomized Phase II and III studies
  • Large observations studies of over 1,000 patients
  • Major biological discovery or breakthrough recently accepted but not yet published in top-ranked journal


If your study meets any of the above criteria and you wish to apply for late breaking privileges, you must submit an abstract by the regular submission deadline June 21, 2013 June 24, 2013 (17:00 PST). To apply for late breaking privileges you must sent an email to, indicating your Abstract ID number and explaining why data is not yet available and when you expect it to become available. The Core Program Committee will then review your abstract and application. If your application is approved you will be sent an email with instructions on how to submit your new data by the end of July 2013. You must submit your Late Breaking Results by August 30, 2013.


How to apply for Late Breaking Privileges:

  • Submit regular abstract (placeholder) on or before regular submission deadline June 21, 2013 (23:59 PST) June 24, 2013 (17:00 PST)
  • Send application email to on or before June 21, 2013 June 24, 2013 (17:00) indicating your abstract ID number and a short explanation why data is not yet available and when you expect it to become available


Important Information regarding ACCME Regulations


Question: Can a commercial employee be listed as a co-author for an abstract?

Yes, a commercial employee can be listed as a co-author.


Question: Can commercial employees present abstracts about their company’s product(s)?

No, except in rare circumstances, this is not permitted. Under rare exceptions, a commercial employee who possesses unique expertise not available otherwise may bepermitted to present. This exception requires a compelling justification and prior written approval by the WCLC 2013 Conference Presidents. Special disclosures and appropriate monitoring by WCLC 2013 program leaders will be required.


Question: Guidelines for presentation content?

Your presentation must give a balanced view of therapeutic options. Use of generic drug names contributes to impartiality. Also, if your presentation includes trade names then trade names from several companies should be used where available, not just trade names From a single company.


Question: Is there a presentation slide template?

Yes, the Conference will provide a template for presentation slides, which will be available at the end of August 2013.



Disclosure. Authors must complete and submit a Disclosure Form prior to the presentation, and that disclosure form shall be complete and truthful to the best of the presenter's knowledge. Authors are required to disclose any relevant financial relationship(s) involving themselves or their spouse/partner within the last 12 months with any proprietary entity producing health care goods or services (excluding non-profit or government organizations) related to the content of the activity. After you submit the completed disclosure form, it is your responsibility to inform IASLC if the status of your financial relationship changes prior to your presentation.

Fair-Balance. Authors are required to prepare fair and balanced presentations that are objective and scientifically rigorous. The presentation will be educational, not promotional, based on the stated objectives of the program and the identified educational needs of the target audience. The presentation/ participation is intended to promote improvements or quality in healthcare and in the public’s best interest.

Unapproved Uses. Presentations that provide information whole or in part related to non-FDA approved uses for drug products and/or devices must clearly acknowledge the unlabeled indications or the investigational nature of their proposed uses to the audience. Presenters who plan to discuss non-FDA approved uses for drug products and/or devices must advise the accredited provider of their intent.


Use of Generic versus Trade Names. When applicable, presenters should use scientific or generic names when referring to products in their lectures and discuss a balanced view of therapeutic options. Should it be necessary to use a trade name, the trade names of all products should be used.

Commercial Supporter Influence. All support associated with a CME activity, whether in the form of an educational grant or not, must be given with the full knowledge and approval of the accredited provider. No other funds from a commercial source shall be paid to the director of the activity, faculty, or others involved with the supported activity. Presenters should not be subject to direct input from a commercial supporter regarding the content of the presentation.

Media and Embargo Policy


Please click here to download the Media and Embargo Policy (pdf) >>